This inventor holds 1 USPTO granted patent. Top assignee: Humboldt-Universitaet Zu Berlin. Active years: 1989.
Company Filing History:
Years Active: 1989
Title: Samuel M. Rapoport: Innovator in Pharmaceutical Chemistry
Introduction
Samuel M. Rapoport is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on 1-(2-hydroxyaryl)-alkane-1-on-oximes. His research focuses on developing compounds with desirable pharmacological properties that can be utilized in various medical applications.
Latest Patents
Rapoport holds a patent for a procedure involving the preparation and use of new 1-(2-hydroxyaryl)-alkane-1-on-oximes. This patent outlines the applicability of these compounds in pharmaceutical preparations. The compounds are characterized by their pharmacologically valuable properties, including anti-asthmatic, anti-anaphylactic, antiphlogistic, antihypertensive, spasmolytic, antirheumatic, and antithrombotic potentials. They are applicable in both human and veterinary medicine for the treatment of asthma bronchiale, allergic diseases, inflammatory and rheumatic diseases, and thrombosis.
Career Highlights
Rapoport's career is marked by his dedication to advancing pharmaceutical science. His work has led to the development of compounds that hold promise for improving therapeutic outcomes in various medical conditions. His innovative approach to drug formulation has garnered attention in the scientific community.
Collaborations
Throughout his career, Rapoport has collaborated with esteemed colleagues, including Tankred Schewe and Hartmut Kuehn. These collaborations have further enriched his research and contributed to the advancement of pharmaceutical chemistry.
Conclusion
Samuel M. Rapoport's contributions to the field of pharmaceutical chemistry through his innovative patents and collaborative efforts highlight his role as a significant inventor. His work continues to impact the development of effective therapeutic agents.